In a phase II, double-blind, randomized, dose-ranging trial in a large cohort of ALS patients, it did not reach statistical significance [ 255 ].
← all excerpts
Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.
1
—
—